tiakis biotech AG, formerly Proteo Biotech AG, located in the north of Germany, is the next generation preventive therapeutic technology company based on its clinical stage pioneering tissue protective drug 'Tiprelestat', which is identical to a human recombinant anti-inflammatory protein. The company is fully dedicated to its novel therapy approach to treat life-threatening unmet medical need diseases. Our approach represents a paradigm shift towards a preventive approach by e.g. protecting against inflammatory organ damage and failure following invasive major surgery, by offering the potential for reversing the vascular pathology of pulmonary arterial hypertension or by prevention of serious disease progression of COVID-19.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Sophienblatt, 40,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- proteo.de
- Keywords
- tissue protective drug, game changing innovation, PAH, Elafin, COMCOVID CLINICAL TRIAL, TIPRELESTAT, human protein elafin.
- HQ
- Kiel, Schleswig-Holstein
Tiakis Biotech Ag Questions
Tiakis Biotech Ag's website is proteo.de
Tiakis Biotech Ag's LinkedIn profile is https://de.linkedin.com/company/tiakis-biotech-ag
Tiakis Biotech Ag has
8 employees.
View email and phone details for 8
employees at Tiakis Biotech Ag.
Tiakis Biotech Ag's industry is
Biotechnology Research
Tiakis Biotech Ag's top competitors are
Kemnet,
Ideas+visions Ltd,
Nueden Bio,
Dinox Gmbh,
Vismarcorp | Strategic Business Consulting,
Evotec,
Founders In Biotech,
Celltec Systems,
Digitart Solution,
Salaam B'y.
Tiakis Biotech Ag's categories are Biotechnology Research
Tiakis Biotech Ag's founding year is 2000
